<DOC>
	<DOCNO>NCT02584777</DOCNO>
	<brief_summary>To evaluate efficacy , safety , pharmacokinetics ( PK ) pharmacodynamics ( PD ) pacritinib Asian subject myelofibrosis ( MF ) , include primary MF ( PMF ) , post-polycythemia vera MF ( PPV-MF ) post-essential thrombocythemia MF ( PET-MF ) .</brief_summary>
	<brief_title>A Phase II Non-Controlled , Open-Label , Efficacy , Safety , Pharmacokinetic , Pharmacodynamic Study Pacritinib Myelofibrosis</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>1 . Intermediate1 , intermediate2 , highrisk PMF , PPVMF PETMF base The Dynamic International Prognostic Scoring System ( DIPSS ) criteria 2 . Palpable splenomegaly ≥5 cm LCM midclavicular line physical examination 3 . TSS ≥13 MPNSAF TSS 2.0 , include inactivity question , base single assessment screen visit 4 . Age ≥18 year old time screening ( minimum age legal consent consistent local regulation , minimum &gt; 18 year age ) 5 . ECOG performance status 0 3 6 . Peripheral blast count &lt; 10 % 7 . Absolute neutrophil count &gt; 500/μL 8 . Participants platelet RBC transfusion dependent eligible 9 . Adequate liver renal function , define liver transaminase ( AST/serum glutamic oxaloacetic transaminase [ SOOT ] alanine aminotransferase [ ALT ] /serum glutamic pyruvic transaminase [ SGPT ] ) ≤3 × upper limit normal ( [ ULN ] , AST/ALT ≤5 × ULN transaminase elevation relate MF ) , direct bilirubin ≤4 × ULN , creatinine ≤2.5 mg/dL 10 . At least 6 month prior splenic irradiation 11 . At least 12 month prior 32P therapy 12 . At least 1 week since prior treatment ( recent dose ) potent CYP3A4 inhibitor inducer 13 . At least 4 week since experimental treatment PMF , PPVMF , PETMF 14 . At least 2 week since treatment PMF , PPVMF , PETMF 15 . If fertile , male female must agree use effective birth control . 16 . Able understand willing complete symptom assessment use patientreported outcome instrument comply treatment study procedure protocol 17 . Able understand willing sign inform consent form ( ICF ) 18 . Participant willing able comply requirement protocol 1 . Any GI metabolic condition could interfere absorption oral medication 2 . Life expectancy &lt; 6 month 3 . Prior treatment JAK2 inhibitor 4 . Completed ASCT , eligible willing complete ASCT 5 . History splenectomy plan undergo splenectomy 6 . Uncontrolled intercurrent illness , include limited ongoing active infection , psychiatric illness , social situation , judgment treat physician , would limit compliance study requirement 7 . Other malignancy within last 3 year , curatively treat basal cell squamous cell skin cancer , carcinoma situ cervix , organ confine , treat nonmetastatic prostate cancer negative prostate specific antigen , situ breast carcinoma complete surgical resection , superficial transitional cell bladder carcinoma 8 . Inflammatory chronic functional bowel disorder , Crohn 's disease , inflammatory bowel disease , chronic diarrhea , constipation 9 . Clinically symptomatic uncontrolled cardiovascular disease 10 . History follow within 6 month prior first dose pacritinib : myocardial infarction , severe/unstable angina , symptomatic congestive heart failure 11 . New York Heart Association Class II , III , IV congestive heart failure 12 . Participants NCI CTCAE ( version 4.03 ) Grade 2 cardiac arrhythmia may consider inclusion , approval medical monitor , arrhythmia stable , asymptomatic unlikely affect participant safety . Participants exclude ongoing cardiac dysrhythmias NCI CTCAE Grade ≥3 , QTc prolongation &gt; 450 m , condition increase risk QT interval prolongation ( eg , heart failure , hypokalemia [ define serum potassium &lt; 3.0 mEq/L persistent refractory correction ] , family history long QT interval syndrome ) 13 . Erythropoietic agent within 28 day prior first dose pacritinib 14 . Thrombopoietic agent within 14 day prior first dose pacritinib 15 . Known seropositivity human immunodeficiency virus syphilis , know active hepatitis A , B C virus infection 16 . Participant participate another clinical study involve IP investigational device within 30 day prior enrollment schedule participate another clinical study involve IP investigational device course study 17 . Participant family member employee investigator 18 . If female , participant pregnant breastfeeding time enrollment . Even breastfeed discontinue , participant enrol study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Post-essential thrombocythemia myelofibrosis</keyword>
	<keyword>Post-Polycythemia Vera Myelofibrosis</keyword>
</DOC>